<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Clin Psychopharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Clin Psychopharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">JCP</journal-id>
      <journal-title-group>
        <journal-title>Journal of Clinical Psychopharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0271-0749</issn>
      <issn pub-type="epub">1533-712X</issn>
      <publisher>
        <publisher-name>Williams And Wilkins</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25203463</article-id>
      <article-id pub-id-type="pmc">4676337</article-id>
      <article-id pub-id-type="publisher-id">JCP14029</article-id>
      <article-id pub-id-type="doi">10.1097/JCP.0000000000000216</article-id>
      <article-id pub-id-type="art-access-id">00023</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editors</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sleep-Related Eating Disorder Associated With Mirtazapine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jeong</surname>
            <given-names>Jong-Hyun</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
      </contrib-group>
      <aff>Department of Psychiatry St Vincent&#x2019;s Hospital College of Medicine The Catholic University of Korea Suwon, Korea</aff>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bahk</surname>
            <given-names>Won-Myong</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
      </contrib-group>
      <aff>Department of Psychiatry St Mary&#x2019;s Hospital College of Medicine The Catholic University of Korea Seoul, Korea <email>wmbahk@catholic.ac.kr</email></aff>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>34</volume>
      <issue>6</issue>
      <fpage>752</fpage>
      <lpage>753</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 by Lippincott Williams &amp; Wilkins</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license>
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="jcp-34-752.pdf"/>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p content-type="salutation">To the Editors</p>
    <p>Sleep-related eating disorder (SRED) is defined as recurrent episodes of involuntary eating and drinking during arousal from sleep with problematic consequences.<xref rid="R1" ref-type="bibr">1</xref> Patients are partially or fully amnestic for this eating behavior. The pathophysiologic mechanism of SRED is uncertain but it has been suggested that it may be related to dopaminergic dysfunction. This theory is supported by the increased prevalence of SRED in restless legs syndrome (RLS).<xref rid="R2" ref-type="bibr">2</xref> Several case reports have been reported in which SRED was associated with zolpidem use.<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R6" ref-type="bibr">6</xref></p>
    <p>The authors present a case of a patient who showed binge eating behavior after sleep-onset due to mirtazapine treatment. The patient showed complete remission after mirtazapine treatment was discontinued. On the basis of a literature review, this is the first report of SRED linked to the use of mirtazapine.</p>
    <sec>
      <title>CASE REPORT</title>
      <p>The subject in this case report is a 24-year-old woman who was brought to the psychiatric ward by her parents and was admitted with depressed mood and suicidal gestures (drug ingestion: zolpidem 50 mg). She reported that she had experienced depressed mood, volition loss, and sleep disturbance for several years and had treated her symptoms with fluoxetine (40 mg/d), trazodone (75 mg/d), and zolpidem (10 mg/d) at a local psychiatric clinic she had visited a year ago. Also, she intermittently experienced night binge eating after sleep-onset but could not remember her eating behavior the next morning. Her weight increased from 50 to 70 kg during a period of 6 months. Physical and neurological examinations and all laboratory tests were normal. There was also no evidence of RLS, periodic limb movement disorder (PLMD), and history of other prior parasomnias. Abnormal eating behavior could be associated with zolpidem and fluoxetine combination therapy. Therefore, we discontinued her all medications at intake and replaced them with mirtazapine (30 mg/d) and clonazepam (0.25 mg/d). Her depressive mood, suicidal ideation, and insomnia improved, and her night binge eating episodes disappeared. After 2 weeks of inpatient therapy, she was discharged from the hospital with markedly improved states.</p>
      <p>However, 2 weeks after discharge, she reported weight gain and night binge eating episodes (4 weeks of mirtazapine and clonazepam use). She usually received her medications around 11 p.m. and went directly to bed. Approximately 1 to 2 hours after sleep-onset, she arose and ate large amounts of food. She seemed to be awake and showed nervousness and irritability when family attempted to stop her behavior. But she could not remember her unusual eating behavior the next morning.</p>
      <p>Even after her mirtazapine dose was reduced to 15 mg/d, her abnormal eating behaviors continued. We finally discontinued mirtazapine, and the binge eating behavior disappeared.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>For a diagnosis of SRED, a patient must experience recurrent episodes of involuntary eating and drinking with problematic results. These involuntary eating and drinking episodes should include 1 or more of the following: consumption of peculiar forms of food or toxic substances, insomnia related to sleep disruption with daytime fatigue or sleepiness, sleep-related injury, dangerous behaviors performed while in pursuit of food or while cooking food, morning anorexia, and adverse health consequences from recurrent binge eating of high-caloric foods.<xref rid="R1" ref-type="bibr">1</xref> Because our patient exhibited recurrent episodes of binge and uncontrollable eating after arousal from sleep, she could not remember her abnormal eating behavior; her symptoms met the diagnostic criteria for SRED. Several drugs, such as zolpidem, triazolam, olanzapine, risperidone, and quetiapine related to SRED,<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R9" ref-type="bibr">9</xref> and topiramate, clonazepam, and dopaminergics showed therapeutic benefits through case reports and small uncontrolled studies.<xref rid="R10" ref-type="bibr">10</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></p>
      <p>Mirtazapine enhances serotonin release by blocking &#x3B1;-2 autoreceptors and heteroreceptors, selectively antagonizing the serotonin 5-HT2 and 5-HT3 receptors in the central and peripheral nervous system. Blockade of 5-HT2 and 5-HT3 receptors may produce antidepressant effects by relieving sleep disturbance or increasing appetite. Mirtazapine also has a potent antagonist effect on histamine 1 receptors, which may augment the sedative and appetite-increasing effects.</p>
      <p>The pathophysiology of SRED is still unclear. However, because SRED is prevalent in patients with RLS and PLMD, there is evidence that SRED may be related to dopaminergic dysfunction.<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref> Some investigators have reported that combined selective &#x3B1;-2 adrenoceptor antagonists and norepinephrine transporter inhibitors caused a marked and selective increase of extracellular dopamine in prefrontal cortex.<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></p>
      <p>However, second-generation antidepressants alone may cause RLS in 9% of patients, and mirtazapine induced or exacerbated RLS in 28% of patients.<xref rid="R17" ref-type="bibr">17</xref> Moreover, recent reports showed an association of mirtazapine with PLMD-like symptoms.<xref rid="R18" ref-type="bibr">18</xref> Although serotonin-mediated dopamine inhibition might be a mechanism,<xref rid="R19" ref-type="bibr">19</xref> it is uncertain which mechanism of mirtazapine causes SRED.</p>
      <p>Here, we report the first case of mirtazapine-related SRED. The use of mirtazapine should, therefore, be considered a possible precipitating factor for developing SRED, and it will not necessarily have an immediate onset.</p>
    </sec>
    <sig-block>
      <sig>Jong-Hyun Jeong, MD, PhD<break/>Department of Psychiatry<break/>St Vincent&#x2019;s Hospital<break/>College of Medicine<break/>The Catholic University of Korea<break/>Suwon, Korea<break/>Won-Myong Bahk, MD, PhD<break/>Department of Psychiatry<break/>St Mary&#x2019;s Hospital<break/>College of Medicine<break/>The Catholic University of Korea<break/>Seoul, Korea<break/>wmbahk@catholic.ac.kr</sig>
    </sig-block>
  </body>
  <back>
    <ack>
      <title>AUTHOR DISCLOSURE INFORMATION</title>
      <p>The authors declare no conflicts of interest.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="book"><collab>American Academy of Sleep Medicine</collab>.
<source><italic>International Classification of Sleep Disorders: Diagnostic and Coding Manual</italic></source>. <edition>2nd ed</edition>
<publisher-loc>Westchester, IL</publisher-loc>: 
<publisher-name>American Academy of Sleep Medicine</publisher-name>; 
<year>2005</year>.</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Provini</surname><given-names>F</given-names></name><name><surname>Antelmi</surname><given-names>E</given-names></name><name><surname>Vignatelli</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Association of restless legs syndrome with nocturnal eating: a case-control study</article-title>.
<source><italic>Mov Disord</italic></source>. 
<year>2009</year>;
<volume>24</volume>:
<fpage>871</fpage>&#x2013;
<lpage>877</lpage>.<pub-id pub-id-type="pmid">19199358</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Morgenthaler</surname><given-names>TI</given-names></name><name><surname>Silber</surname><given-names>MH</given-names></name></person-group>
<article-title>Amnestic sleep-related eating disorder associated with zolpidem</article-title>.
<source><italic>Sleep Med</italic></source>. 
<year>2002</year>;
<volume>3</volume>:
<fpage>323</fpage>&#x2013;
<lpage>327</lpage>.<pub-id pub-id-type="pmid">14592194</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Najjar</surname><given-names>M</given-names></name></person-group>
<article-title>Zolpidem and amnestic sleep related eating disorder</article-title>.
<source><italic>J Clin Sleep Med</italic></source>. 
<year>2007</year>;
<volume>3</volume>:
<fpage>637</fpage>&#x2013;
<lpage>638</lpage>.<pub-id pub-id-type="pmid">17993047</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Dang</surname><given-names>A</given-names></name><name><surname>Garg</surname><given-names>G</given-names></name><name><surname>Rataboli</surname><given-names>PV</given-names></name></person-group>
<article-title>Zolpidem induced Nocturnal Sleep-Related Eating Disorder (NSRED) in a male patient</article-title>.
<source><italic>Int J Eat Disord</italic></source>. 
<year>2009</year>;
<volume>42</volume>:
<fpage>385</fpage>&#x2013;
<lpage>386</lpage>.<pub-id pub-id-type="pmid">19107832</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Yun</surname><given-names>CH</given-names></name><name><surname>Ji</surname><given-names>KH</given-names></name></person-group>
<article-title>Zolpidem-induced sleep-related eating disorder</article-title>.
<source><italic>J Neurol Sci</italic></source>. 
<year>2010</year>;
<volume>288</volume>:
<fpage>200</fpage>&#x2013;
<lpage>201</lpage>.<pub-id pub-id-type="pmid">19822330</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Paquet</surname><given-names>V</given-names></name><name><surname>Strul</surname><given-names>J</given-names></name><name><surname>Servais</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Sleep-related eating disorder induced by olanzapine</article-title>.
<source><italic>J Clin Psychiatry</italic></source>. 
<year>2002</year>;
<volume>63</volume>:
<fpage>597</fpage>.<pub-id pub-id-type="pmid">12143918</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Tamanna</surname><given-names>S</given-names></name><name><surname>Ullah</surname><given-names>MI</given-names></name><name><surname>Pope</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Quetiapine-induced sleep-related eating disorder-like behavior: a case series</article-title>.
<source><italic>J Med Case Rep</italic></source>. 
<year>2012</year>;
<volume>6</volume>:
<fpage>380</fpage>.<pub-id pub-id-type="pmid">23130910</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Lu</surname><given-names>ML</given-names></name><name><surname>Shen</surname><given-names>WW</given-names></name></person-group>
<article-title>Sleep-related eating disorder induced by risperidone</article-title>.
<source><italic>J Clin Psychiatry</italic></source>. 
<year>2004</year>;
<volume>65</volume>:
<fpage>273</fpage>&#x2013;
<lpage>274</lpage>.<pub-id pub-id-type="pmid">15003084</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Schenck</surname><given-names>CH</given-names></name><name><surname>Hurwitz</surname><given-names>TD</given-names></name><name><surname>O&#x2019;Connor</surname><given-names>KA</given-names></name><etal/></person-group>
<article-title>Additional categories of sleep-related eating disorders and the current status of treatment</article-title>.
<source><italic>Sleep</italic></source>. 
<year>1993</year>;
<volume>16</volume>:
<fpage>457</fpage>&#x2013;
<lpage>466</lpage>.<pub-id pub-id-type="pmid">8104356</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Provini</surname><given-names>F</given-names></name><name><surname>Albani</surname><given-names>F</given-names></name><name><surname>Vetrugno</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder</article-title>.
<source><italic>Eur J Neurol</italic></source>. 
<year>2005</year>;
<volume>12</volume>:
<fpage>432</fpage>&#x2013;
<lpage>436</lpage>.<pub-id pub-id-type="pmid">15885046</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Yoshimura</surname><given-names>R</given-names></name><name><surname>Takano</surname><given-names>M</given-names></name></person-group>
<article-title>Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report</article-title>.
<source><italic>Case Rep Med</italic></source>. 
<year>2012</year>;
<volume>2012</volume>:
<fpage>893681</fpage>.<pub-id pub-id-type="pmid">22481958</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Winkelman</surname><given-names>JW</given-names></name></person-group>
<article-title>Clinical and polysomnographic features of sleep-related eating disorder</article-title>.
<source><italic>J Clin Psychiatry</italic></source>. 
<year>1998</year>;
<volume>59</volume>:
<fpage>14</fpage>&#x2013;
<lpage>19</lpage>.<pub-id pub-id-type="pmid">9491060</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Schenck</surname><given-names>CH</given-names></name><name><surname>Hurwitz</surname><given-names>TD</given-names></name><name><surname>Bundlie</surname><given-names>SR</given-names></name><etal/></person-group>
<article-title>Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders</article-title>.
<source><italic>Sleep</italic></source>. 
<year>1991</year>;
<volume>14</volume>:
<fpage>419</fpage>&#x2013;
<lpage>431</lpage>.<pub-id pub-id-type="pmid">1759095</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Masana</surname><given-names>M</given-names></name><name><surname>Bortolozzi</surname><given-names>A</given-names></name><name><surname>Artigas</surname><given-names>F</given-names></name></person-group>
<article-title>Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia</article-title>.
<source><italic>Int J Neuropsychopharmacol</italic></source>. 
<year>2011</year>;
<volume>14</volume>:
<fpage>53</fpage>&#x2013;
<lpage>68</lpage>.<pub-id pub-id-type="pmid">20701825</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Masana</surname><given-names>M</given-names></name><name><surname>Castane</surname><given-names>A</given-names></name><name><surname>Santana</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies</article-title>.
<source><italic>Neuropharmacology</italic></source>. 
<year>2012</year>;
<volume>63</volume>:
<fpage>675</fpage>&#x2013;
<lpage>684</lpage>.<pub-id pub-id-type="pmid">22652058</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Rottach</surname><given-names>KG</given-names></name><name><surname>Schaner</surname><given-names>BM</given-names></name><name><surname>Kirch</surname><given-names>MH</given-names></name><etal/></person-group>
<article-title>Restless legs syndrome as side effect of second generation antidepressants</article-title>.
<source><italic>J Psychiatr Res</italic></source>. 
<year>2008</year>;
<volume>43</volume>:
<fpage>70</fpage>&#x2013;
<lpage>75</lpage>.<pub-id pub-id-type="pmid">18468624</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Mattoo</surname><given-names>SK</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>PLMD-like nocturnal movements with mirtazapine</article-title>.
<source><italic>Gen Hosp Psychiatry</italic></source>. 
<year>2013</year>;
<volume>35</volume>:
<fpage>576.e7</fpage>&#x2013;
<lpage>576.e8</lpage>.<pub-id pub-id-type="pmid">23273829</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group><name><surname>Kugaya</surname><given-names>A</given-names></name><name><surname>Seneca</surname><given-names>NM</given-names></name><name><surname>Snyder</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration</article-title>.
<source><italic>Neuropsychopharmacology</italic></source>. 
<year>2003</year>;
<volume>28</volume>:
<fpage>413</fpage>&#x2013;
<lpage>420</lpage>.<pub-id pub-id-type="pmid">12589396</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
